Spark Investment Management LLC Protagonist Therapeutics, Inc Transaction History

Spark Investment Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$6.19 - $18.84 $144,245 - $439,028	-23,303 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$5.4 - $9.22 $3,223 - $5,504	-597 Reduced 2.5%	23,303 $164,000
Q4 2019 Feb 11, 2020	BUY	$4.69 - $13.45 $112,091 - $321,455	23,900 New	23,900 $168,000
Q2 2019 Aug 12, 2019	SELL	$8.98 - $12.96 $90,698 - $130,896	-10,100 Closed	0 $0
Q1 2019 May 07, 2019	SELL	$6.5 - $13.77 $549,250 - $1.16 Million	-84,500 Reduced 89.32%	10,100 $126,000
Q4 2018 Feb 12, 2019	SELL	$6.3 - $10.44 $278,460 - $461,448	-44,200 Reduced 31.84%	94,600 $636,000
Q3 2018 Nov 13, 2018	BUY	$6.82 - $11.26 $3,410 - $5,630	500 Added 0.36%	138,800 $1.43 Million
Q2 2018 Aug 08, 2018	BUY	$5.99 - $9.1 $339,034 - $515,060	56,600 Added 69.28%	138,300 $929,000
Q1 2018 May 10, 2018	BUY	$8.46 - $23.08 $509,292 - $1.39 Million	60,200 Added 280.0%	81,700 $701,000
Q4 2017 Feb 12, 2018	BUY	$14.47 - $20.8 $311,105 - $447,200	21,500	21,500 $447,000

254

58.9M

189K

191K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.9B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Spark Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Spark Investment Management LLC with notifications on news.